EPDR1 Correlates with Immune Cell Infiltration in Hepatocellular Carcinoma and Can Be Used As a Prognostic Biomarker

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2020 Sep 16

PMID 32935479

Citations 14

Authors

Ruochan Chen

Yiya Zhang

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) has high mortality rate and is a serious disease burden globally. EPDR1 (ependymin related 1) is a member of piscine brain glycoproteins and is involved in cell adhesion. The gene expression, prognostic, and clinicopathological related data for EPDR1 were obtained from multiple transcriptome databases. Protein level of EPDR1 in HCC was verified using human protein atlas and CPTAC databases. EPDR1 co-expressed genes were identified using LinkedOmics. Functional analysis of the co-expressed genes was performed using gene set enrichment analysis, Gene Ontology, and KEGG. Statistical analysis was conducted in R. The relationship between EPDR1 expression and immune cell infiltration was analyzed using TIMER and CIBERSORT. The expression of EPDR1 was found to be significantly higher in HCC than in normal tissues. Further, EPDR1 level was correlated with advanced stage of HCC. EPDR1 was associated with multiple signaling, as well as cancer and apoptotic pathways. Further, EPDR1 expression was significantly correlated with purity and infiltration levels of various immune cells as well as immune signatures. This is the first study to report the role of EPDR1 in HCC. EPDR1 can be used as a novel prognostic biomarker as well as an effective target for diagnosis and treatment in HCC.

Citing Articles

The Proteasome-Family-Members-Based Prognostic Model Improves the Risk Classification for Adult Acute Myeloid Leukemia.

Sheng G, Tao J, Jin P, Li Y, Jin W, Wang K Biomedicines. 2024; 12(9).

PMID: 39335660 PMC: 11429122. DOI: 10.3390/biomedicines12092147.

EPDR1 promotes PD-L1 expression and tumor immune evasion by inhibiting TRIM21-dependent ubiquitylation of IkappaB kinase-β.

Qian X, Cai J, Zhang Y, Shen S, Wang M, Liu S EMBO J. 2024; 43(19):4248-4273.

PMID: 39152265 PMC: 11445549. DOI: 10.1038/s44318-024-00201-6.

Identification of bone mineral density associated genes with shared genetic architectures across multiple tissues: Functional insights for EPDR1, PKDCC, and SPTBN1.

Jung J, Wu Q PLoS One. 2024; 19(4):e0300535.

PMID: 38683846 PMC: 11057974. DOI: 10.1371/journal.pone.0300535.

Hypoxia-induced miR-181a-5p up-regulation reduces epirubicin sensitivity in breast cancer cells through inhibiting EPDR1/TRPC1 to activate PI3K/AKT signaling pathway.

Zhang Y, Guan Y, Zheng X, Li C BMC Cancer. 2024; 24(1):167.

PMID: 38308220 PMC: 10835859. DOI: 10.1186/s12885-024-11906-6.

EPDR1 levels and tumor budding predict and affect the prognosis of bladder carcinoma.

Yang Y, Xu H, Zhu H, Yuan D, Zhang H, Liu Z Front Oncol. 2022; 12:986006.

PMID: 36276104 PMC: 9585273. DOI: 10.3389/fonc.2022.986006.

References

Wang J, Ha J, Lopez A, Bhuket T, Liu B, Wong R . Medicaid and Uninsured Hepatocellular Carcinoma Patients Have More Advanced Tumor Stage and Are Less Likely to Receive Treatment. J Clin Gastroenterol. 2017; 52(5):437-443. DOI: 10.1097/MCG.0000000000000859. View

Zhu A, Kang Y, Yen C, Finn R, Galle P, Llovet J . Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(2):282-296. DOI: 10.1016/S1470-2045(18)30937-9. View

Suga T, Iwakawa M, Tsuji H, Ishikawa H, Oda E, Noda S . Influence of multiple genetic polymorphisms on genitourinary morbidity after carbon ion radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 72(3):808-13. DOI: 10.1016/j.ijrobp.2008.01.029. View

Gu Y, Li X, Bi Y, Zheng Y, Wang J, Li X . CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma. Aging (Albany NY). 2020; 12(1):784-807. PMC: 6977663. DOI: 10.18632/aging.102656. View

Couri T, Pillai A . Goals and targets for personalized therapy for HCC. Hepatol Int. 2019; 13(2):125-137. DOI: 10.1007/s12072-018-9919-1. View

Dolmans G, Werker P, Hennies H, Furniss D, Festen E, Franke L . Wnt signaling and Dupuytren's disease. N Engl J Med. 2011; 365(4):307-17. DOI: 10.1056/NEJMoa1101029. View

Hemnes A, Trammell A, Archer S, Rich S, Yu C, Nian H . Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. Circulation. 2014; 131(4):401-9. PMC: 4308423. DOI: 10.1161/CIRCULATIONAHA.114.013317. View

Chen R, Wang J, Kuang X, Peng F, Fu Y, Huang Y . Integrated analysis of microRNA and mRNA expression profiles in HBx-expressing hepatic cells. World J Gastroenterol. 2017; 23(10):1787-1795. PMC: 5352919. DOI: 10.3748/wjg.v23.i10.1787. View

Ye F, Zhang H, Yang Y, Hu H, Sze S, Meng W . Comparative proteome analysis of 3T3-L1 adipocyte differentiation using iTRAQ-coupled 2D LC-MS/MS. J Cell Biochem. 2011; 112(10):3002-14. DOI: 10.1002/jcb.23223. View

10.

Thein H, Qiao Y, Zaheen A, Jembere N, Sapisochin G, Chan K . Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting. PLoS One. 2017; 12(10):e0185198. PMC: 5634563. DOI: 10.1371/journal.pone.0185198. View

11.

Chen R, Zhang Y . EPDR1 correlates with immune cell infiltration in hepatocellular carcinoma and can be used as a prognostic biomarker. J Cell Mol Med. 2020; 24(20):12107-12118. PMC: 7579695. DOI: 10.1111/jcmm.15852. View

12.

Chen R, Xie Y, Zhong X, Fu Y, Huang Y, Zhen Y . Novel chemokine-like activities of histones in tumor metastasis. Oncotarget. 2016; 7(38):61728-61740. PMC: 5308686. DOI: 10.18632/oncotarget.11226. View

13.

Kouznetsova I, Chwieralski C, Balder R, Hinz M, Braun A, Krug N . Induced trefoil factor family 1 expression by trans-differentiating Clara cells in a murine asthma model. Am J Respir Cell Mol Biol. 2006; 36(3):286-95. DOI: 10.1165/rcmb.2006-0008OC. View

14.

Shlomai A, de Jong Y, Rice C . Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014; 26:78-88. PMC: 4048791. DOI: 10.1016/j.semcancer.2014.01.004. View

15.

Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R . Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2015; 63(1):173-84. PMC: 4688087. DOI: 10.1002/hep.28251. View

16.

Qian B, Pollard J . Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141(1):39-51. PMC: 4994190. DOI: 10.1016/j.cell.2010.03.014. View

17.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

18.

Li S, Huang Y, Huang Y, Fu Y, Tang D, Kang R . The long non-coding RNA TP73-AS1 modulates HCC cell proliferation through miR-200a-dependent HMGB1/RAGE regulation. J Exp Clin Cancer Res. 2017; 36(1):51. PMC: 5389141. DOI: 10.1186/s13046-017-0519-z. View

19.

Zhang Q, He Y, Luo N, Patel S, Han Y, Gao R . Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma. Cell. 2019; 179(4):829-845.e20. DOI: 10.1016/j.cell.2019.10.003. View

20.

. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell. 2017; 169(7):1327-1341.e23. PMC: 5680778. DOI: 10.1016/j.cell.2017.05.046. View